Over the following years other anti-TNF inhibitors, including adalimumab, infliximab, and golimumab, the IL-6 inhibitor tocilizumab, and costimulatory disruption abatacept were tested in RCTs that included patients with polyarticular JIA [32–34]. This evidence concerns the gene IL6 and polyarticular juvenile idiopathic arthritis.